References
- Parshall MB, Schwartzstein RM, Adams L, Banzett RB, Manning HL, Bourbeau J, etal. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012; 185: 435–52.
- Gronseth R, Vollmer WM, Hardie JA, Olafsdottir IS, Lamprecht B, Buist AS, etal. Predictors of dyspnoea prevalence: results from the BOLD study. Eur Respir J. 2014; 43: 1610–20.
- Moens K, Higginson IJ, Harding R. Are there differences in the prevalence of palliative care-related problems in people living with advanced cancer and eight non-cancer conditions? A systematic review. J Pain Symptom Manag. 2014; 48: 660–77.
- Ekstrom MP, Abernethy AP, Currow DC. The management of chronic breathlessness in patients with advanced and terminal illness. BMJ. 2015; 349: g7617.
- From the global strategy for the diagnosis, management and prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2016. Available from: http://wwwGoldcopdOrg/ [cited 31 October 2016]..
- Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest. 2002; 121: 1434–40.
- Ahmed A, Aronow WS, Fleg JL. Higher New York Heart Association classes and increased mortality and hospitalization in heart failure patients with preserved left ventricular function. Am Heart J. 2006; 151: 444–50.
- Abidov A, Rozanski A, Hachamovitch R, Hayes SW, Aboul-Enein F, Cohen I, etal. Prognostic significance of dyspnea in patients referred for cardiac stress testing. N Engl J Med. 2005; 353: 1889–98.
- Johnson MJ, Currow DC, Booth S. Prevalence and assessment of breathlessness in the clinical setting. Expert Rev Respir Med. 2014; 8: 151–61.
- Banzett RB, O'Donnell CR, Guilfoyle TE, Parshall MB, Schwartzstein RM, Meek PM, etal. Multidimensional dyspnea profile: an instrument for clinical and laboratory research. Eur Respir J. 2015; 45: 1681–91.
- Banzett RB, Adams L, O'Donnell CR, Gilman SA, Lansing RW, Schwartzstein RM. Using laboratory models to test treatment: morphine reduces dyspnea and hypercapnic ventilatory response. Am J Respir Crit Care Med. 2011; 184: 920–7.
- Wadell K, Webb KA, Preston ME, Amornputtisathaporn N, Samis L, Patelli J, etal. Impact of pulmonary rehabilitation on the major dimensions of dyspnea in COPD. COPD. 2013; 10: 425–35.
- Meek PM, Banzett R, Parshall MB, Gracely RH, Schwartzstein RM, Lansing R. Reliability and validity of the multidimensional dyspnea profile. Chest. 2012; 141: 1546–53.
- Parshall MB, Meek PM, Sklar D, Alcock J, Bittner P. Test-retest reliability of multidimensional dyspnea profile recall ratings in the emergency department: a prospective, longitudinal study. BMC Emerg Med. 2012; 12: 6.
- Morelot-Panzini C, Gilet H, Aguilaniu B, Devillier P, Didier A, Perez T, etal. Real-life assessment of the multidimensional nature of dyspnoea in COPD outpatients. Eur Respir J. 2016; 47: 1668–79.
- Wild D, Eremenco S, Mear I, Martin M, Houchin C, Gawlicki M, etal. Multinational trials – recommendations on the translations required, approaches to using the same language in different countries, and the approaches to support pooling the data: the ISPOR Patient-Reported Outcomes Translation and Linguistic Validation Good Research Practices Task Force report. Value Health. 2009; 12: 430–40.
- Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A, etal. Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health. 2005; 8: 94–104.
- Ekstrom M, Sundh J, Larsson K. Patient reported outcome measures in chronic obstructive pulmonary disease: which to use?. Expert Rev Respir Med. 2016; 10: 351–62.